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Abstract 
The central dogma of biology, until not long ago, held that genetic information stored 
on DNA molecules was translated into the final protein products through RNA as 
intermediate molecules. Then, an additional level of complexity in the regulation of genome 
expression was added, implicating new classes of RNA molecules called non-coding RNA 
(ncRNA). These ncRNA are also often referred to as functional RNA in that, although they do 
not contain the capacity to encode proteins, do have a function as RNA molecules. They have 
been thus far considered as truly non-coding RNA since no ORF long enough to be 
considered, nor protein, have been associated with them. However, the recent identification 
and characterization of bifunctional RNA, i.e. RNA for which both coding capacity and 
activity as functional RNA have been reported, suggests that a definite categorization of some 
RNA molecules is far from being straightforward. 
Indeed, several RNA primarily classified as non-protein-coding RNA has been showed 
to hold coding capacities and associated peptides. Conversely, mRNA, usually regarded as 
strictly protein-coding, may act as functional RNA molecules. Here, we describe several 
examples of these bifunctional RNA that have been already characterized from bacteria to 
mammals. We also extend this concept to fortuitous acquisition of dual function in 
pathological conditions and to the recently highlighted duality between information carried by 
a gene and its pseudogenes counterparts. 
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1. Introduction  
It is now well admitted that one needs to think beyond the canonical protein-coding 
function when it comes to study the functionality of the genome. While the protein-coding 
gene count of eukaryotic genomes is relatively poor and not well correlated with organism 
complexity, the increasing awareness that most of the human genome may be transcribed, and 
that the number of genes that do not code for proteins is much larger than expected [1-3], 
added some levels of sophistication in the way organisms gain their phenotypic variability [4]. 
Besides expression of protein-coding genes being regulated through alternative splicing and 
regulation of promoter strength/usage, an additional level in the regulation of genome 
expression involves RNA molecules called non-coding RNA (ncRNA). ncRNA do not encode 
for protein and mechanisms whereby they play key roles in the regulations of complex 
organisms remain largely obscure (For a simplified chronological chart, see Figure 1).  
[Figure 1 may be inserted here] 
ncRNA are often referred to as functional RNA in that, although they do not hold a 
capacity to encode proteins, they have a function as RNA molecules. The role of ribosomal 
RNA (rRNA), transfer RNA (tRNA), and more recently microRNA (miRNA), in protein 
translation, or small nuclear RNA (snRNA) in splicing of messenger RNA (mRNA), is now 
well documented. Fascinatingly, other fundamental mechanisms may also depend on new 
classes of ncRNA. Many long ncRNA (lncRNA), so called to distinguish them from small 
interfering RNA (siRNA) and miRNA, function as RNA scaffolds implicated in chromosome 
architecture, base-pairing-dependent mRNA targeting influencing mRNA turnover or 
developmental timing of protein expression, and may also directly regulate transcription and 
alternative splicing [5-14]. Examples include B2-SINE that can directly bind RNA 
polymerase II to inhibit gene expression under heat-shock conditions [15], or 7SK that 
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represses transcription elongation through its interaction with the basal transcription factor P-
TEFb [16; 17]. Xist and centromeric RNA contribute to assembly of specific chromatin 
structures at the inactive X in female cells and centromeres respectively, by recruiting histone 
variants and/or serving as a scaffold for complexes located at these regions [7; 14; 18]. The 
activity of transcription factors can also be regulated through their sequestration in the 
cytoplasm of the cells by ncRNA. For example, NRON (non-coding repressor of NFAT) 
binds to and prevents the nuclear localization, and therefore the action, of the transcriptional 
activator NFAT [19]. 
These RNA are thus far considered to be truly non-coding RNA since no open reading 
frame (ORF) long enough to be considered, nor protein, have been associated with them. The 
class of long non-coding RNA also includes many mRNA-like non-coding RNA (mlncRNA), 
identified in high-throughput studies of the transcriptome, which can undergo splicing, are 
capped and polyadenylated, but contain little or no protein-coding potential [20-22]. Instead, 
they may influence cellular activity through specific sequences and/or RNA-folding 
structures. 
Despite accumulating data on so-called non-coding RNA, it is likely that we are only 
watching the tip of the iceberg. We review here what is currently emerging as an increasingly 
fascinating area in the field, along which many RNA, usually regarded as strictly protein-
coding mRNA, may fulfill additional non-coding functions. Conversely, many RNA primarily 
classified as non-protein-coding RNA hold uncovered coding capacities. We focus on this 
duality within the “RNA world” that may contribute to increase the spectrum of gene 
function, by describing examples of these bifunctional RNA that have been already 
characterized from bacteria to mammals. Attention must also be drawn to apparently 
conflicting new functions of mRNA in the control of protein activity by influencing their sub-
cellular localization or transport in normal or pathological conditions. Finally, we extended 
 5 
this concept to the recently highlighted duality between information carried by a gene and its 
pseudogenes counterparts. 
 
2. Examples of coding vs. non-coding swing during evolution 
It is not clear why during evolution some genes lost their protein-coding function by 
mutation or conversely, why non-coding or pseudogenes gained the capacity to encode 
proteins. Nevertheless, in both cases the result is acquisition of novel functions, mainly due to 
transposon integration. We review here well-documented examples of such changes, which 
primarily highlights that genes indeed evolved to acquire new or additional functions, yet, the 
effector molecule can be a protein or an RNA depending on the organism considered.  
 
2.1 From coding to non-coding: the example of XIC (X-Inactivation Center) genes 
In female mammals, one of the two X chromosomes is transcriptionally silenced during 
early development to compensate for the double dose of X-linked genes (For recent reviews 
see [23-25]). In mouse and human, this process of X inactivation is highly dependent on a 
locus located on the X chromosome itself, the X Inactivation Center (XIC) [26; 27]. The XIC 
genomic region contains several genes of which six produce untranslated RNA (reviewed in 
[28; 29]), including the two major players Xist and its antisense counterpart Tsix [30-32]. X 
inactivation is initiated through expression of Xist RNA from, and coating of, the inactive X 
chromosome (Xi), leading to Xi chromosome-wide transcriptional silencing (reviewed in 
[33]). Tsix acts in cis to negatively regulate Xist, through modulation of chromatin over the 
Xist promoter, thereby affecting the ability of a given chromosome to be inactivated 
(reviewed in [34]). While the role of Xist and Tsix is well documented, no defined function in 
X-chromosome inactivation is known for the other neighboring non-coding genes. 
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As mentioned above, the Xist gene is expressed exclusively from the inactive X 
chromosome as a large processed RNA for which no protein product has been identified. 
However, sequence comparison between species revealed that evolution of Xist gene was 
accompanied by pseudogenization of a coding gene located within a region of synteny 
between chicken and human and by integration of mobile elements [35; 36]. Two exons of 
Xist containing frame shift mutations derive from the Lnx3 gene, which in chicken produces 
an mRNA encoding a protein similar to PDZ domain containing ring finger 1 (ligand of 
NUMB-protein X/PDZRN (PDZ domain-containing RING finger)). In fact, pseudogenization 
and invasion by transposable elements appear to have affected other genes in the XIC 
syntenic locus. The loss of protein-coding function in Lnx3 (to become Xist) coincides with 
the loss of function of several other protein genes (Fip1l2, Rasl11c, UspL and Wave4) to 
become transcribed but untranslated Tsx, Jpx and Ftx genes [35]). These genes seem to have 
evolved a little bit further since some of them like Tsx are still functionally transcribed and 
translated in mouse and rat [28] but not in human [37].  
It is interesting to note that although pseudogenization led to disruption of the Lnx3 
ORF and loss of protein-coding function for the new Xist gene, transposon insertions led to 
the appearance of new functional domains. These domains, like the repeat A in exon 1, then 
became necessary for the silencing function of Xist [38]. As suggested earlier [35] this 
example of how a protein-coding gene lost its protein-coding function by mutation but gained 
a new function due to transposon integration is not a unique case, but is a more wide-spread 
phenomenon applying to other ncRNA genes and pseudogenes with new functions.  
 
2.2 From non-coding to coding: transposable elements 
Just like genes losing their protein coding capacity through insertion of mobile 
elements, the reverse situation exists in which transposable elements (TE) were “exonized”. 
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In this process, TE insertion into introns was probably followed by mutations that allowed the 
RNA splicing machinery to recruit part of the inserted transposable element into coding 
regions as novel exons [39]. Exonization can therefore permit the emergence of new 
regulatory motifs and new protein functions, without necessarily eliminating the original 
function of a protein. In that respect, retrotransposons and other classes of transposable 
elements are now generally considered as significant contributors to genome evolution [40] 
influencing genome size, function, and structure [41; 42]. Indeed, about half of the human 
genome is derived from transposable elements (TE), with about 8% of Long Terminal Repeat 
(LTR) and 33% of non-LTR retro-elements [41; 43]. In addition, TE motifs are found in the 
coding sequence of 4% of human genes, suggesting that these repeat-forming elements can 
become exonized (reviewed in [44; 45]). Strikingly, in some cases, distinct exons are 
exclusively composed of LTR sequences. For example, the 4th, 5th, and 14th exons of 
interleukin 22 receptor alpha 2 (IL22RA2, NM_052962), SET domain, bifurcated 2 (SETDB2, 
NM_031915), and methyl-CpG binding domain protein 1 (MBD1, NM_015845) genes, 
respectively, are entirely formed by LTR sequences [45] and the BCL2/adenovirus E1B 
19kDa interacting protein 3 (BNIP3, NM_004052) is 97% made up of sequences from a 
human retrovirus [46]. 
 
3. Bifunctional RNA 
Bifunctional RNA can be defined as RNA that have the intrinsic ability to produce two 
distinct functions. A class of bifunctional RNA, on which we will not focus here, produce two 
different types of ncRNA like a snoRNA and a miRNA, involved in distinct biological 
pathways [47]. A more remarkable category now contains several examples of RNA which 
serve both as intermediate molecules translated into protein and as functional RNA (Box1). 
As we will see below, these functions are in essence mechanistically distinct but can be 
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physiologically redundant, and do not necessarily co-exist within the same cell or at the same 
period of the life of the cell.  
[BOX 1 may be inserted here]  
 
3.1 SgrS, a small RNA and its SgrT protein counterpart (Escherichia coli) 
Sugar phosphate stress in Escherichia coli is controlled by a 227-nt small RNA (sRNA) 
SgrS (sugar transport-related small RNA) and SgrR, which encodes the transcriptional 
activator required for SgrS transcription [48]. SgrS expression is induced by intracellular 
accumulation of glucose-6-phosphate (G6P) and is necessary for full recovery from glucose-
phosphate stress by inducing the degradation of glucose transporters. SgrS holds two distinct 
functions that inhibit glucose transport independently. SgrS is first a riboregulator, i.e. an 
RNA functioning as a genetic regulator, a class of RNA widely described in bacteria [49; 50]. 
Its 3' region is partially complementary to the translation initiation region of mRNA that 
encode glucose transporters, leading to a base pairing-dependent translational repression and 
degradation of these target mRNA [106]. In addition, the 5' end of SgrS encodes the 43-
amino-acid polypeptide SgrT, also implicated in the inhibition of glucose transport, yet by a 
mechanism independent of the base-pairing activity [51]. It was proposed that SgrT could 
trigger a rapid response to stress by reducing influx of sugar phosphates without affecting 
levels or stability of the transport proteins, whereas the riboregulation activity of SgrS could 
result from an adaptation to prolonged stress, by stopping synthesis of new transporters [51].  
SgrS therefore shows features of a bifunctional sRNA that encodes physiologically 
redundant but mechanistically distinct functions implicated in the same response to stress. Of 
note, homologs of the transcription factor SgrR and its target sRNA SgrS, primarily identified 
in E. coli, have been identified in a variety of other enteric bacterial species [107].  
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3.2 RNAIII (Staphylococcus aureus) 
The small RNAIII is the intracellular effector of the quorum-sensing system, a system 
used by bacteria to coordinate their gene expression according to their local density of 
population, in the nosocomial pathogen Staphylococcus aureus. RNAIII represents a 
paradigm in the field of regulatory RNA linked to bacterial pathogenesis. Whereas it was 
originally described as a mRNA coding the δ-hemolysin peptide, further analysis revealed 
that, in addition to the 26 amino acid ORF in its 5′ region [54; 55], RNAIII acted as an 
antisense regulator of virulence and surface protein synthesis through its 3′ region [52; 53]. 
Base pairing of the 3′ domain of RNAIII to target mRNA that encode a class of virulence 
factors, or the transcriptional regulatory protein Rot, occlude ribosome binding site leading to 
the repression of translation initiation and triggering of endoribonuclease III-mediated 
hydrolysis [108; 109]. 
Thus, RNA III of S. aureus is a master regulator of Staphylococcal virulence that also 
meets the definition of a bifunctional sRNA. It acts as a mRNA that encodes the δ-hemolysin 
peptide, which controls the switch between early expression of surface proteins and late 
expression of several exotoxins, as well as a trans-acting RNA, which modulates the 
production of S. aureus extracellular toxins and enzymes, through a base pairing mechanism 
on mRNA targets [55; 108-111]. Although precise mechanisms are still unclear, it was 
proposed that the δ-hemolysin protein may act in conjunction with its RNAIII transcript 
counterpart to regulate the expression of exoprotein genes [55; 112; 113]. 
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3.3 tmRNA (Bacteria) 
Transfer-messenger RNA (tmRNA), also known as SsrA or 10Sa RNA, is a 
bifunctional RNA that may look odd in the world of coding/non-coding RNA reviewed here 
in that it combines the functions of tRNA and mRNA. Trans-translation and the tmRNA 
system perform translational surveillance to rescue ribosomes stalled on defective mRNA, 
missing a stop codon for instance, and contribute to the degradation of incompletely 
synthesized peptides, in all eubacteria and some eukaryotic organelles [56; 57]. tmRNA acts 
initially as transfer RNA (tRNA), being aminoacylated at its 3′-end, to add alanine to the 
stalled polypeptide chain. Translation then switches from the defective mRNA to an internal 
tmRNA short open reading frame (ORF) of 8-35 residues, whereby the mRNA-like domain of 
tmRNA replaces the nonstop messenger RNA bound to the ribosome [56-60]. The 
degradation tag encoded by the ORF targets the incompletely synthesized protein for 
degradation by cellular proteases. The stop codon at the end of the tmRNA ORF provides the 
missing termination signal, which causes the release of the synthesized polypeptide and the 
dissociation of ribosomal subunits.  
tmRNA dual function primarily serves the quality control of mRNA. A general role for 
trans-translation in monitoring protein folding and perhaps other co-translational processes 
has been proposed recently [56-60].  
[Box 2 may be inserted here]  
 
3.4 enod40, early nodulin 40 (Green plants) 
When leguminous plants enter into symbiosis with N2-fixing bacteria, a number of 
genes are coordinately expressed from both partners. The peculiar gene enod40 is rapidly 
induced and highly expressed in the dividing root cortical cells, leading to nodule formation 
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as well as in other non-symbiotic organs [123]. The enod40 gene is present in all legumes 
studied so far, and is also found in many non-legume plants. In plants, enod40 mRNA (about 
600 bp) contains two short overlapping ORF leading to translation of two peptides of 10-25 
amino acids [124], implicated in the promotion of division of cortical cells, probably through 
binding to sucrose synthase and regulation of sucrose utilization in nodules. In addition, its 
core region shows hallmarks of structural RNA, namely a strongly conserved secondary 
structure topology despite very high sequence diversity. The putative RNA structural 
elements are more conserved than the peptide sequence, suggesting that the general 
mechanism of enod40 action might be determined by the RNA [62]. Deletion of the region 
spanning the predicted RNA structure, but leaving the sORFs intact, did not affect translation 
of the mRNA but resulted in a significantly decreased biological activity. The stem-loop 
structures mediate interaction with the nuclear RNA-binding protein MtRBP1 [61]. One 
hypothesis is that the RNA itself, through integration into a RNP, will be a major determinant 
of enod40 function conferring specificity for the recognition of mRNA targets. The 
interactions are independent of enod40 ORFs translation and affects MtRBP1 localization 
during nodule development, changing from nuclear speckles, involved in splicing and RNA 
regulatory processes, to cytoplasmic granules, suggesting the implication of enod40 RNA in 
the cytoplasmic export of nuclear proteins, independently of a protein targeting motif. 
This set of data pointed out the dual function of enod40 as both a peptide producing and 
a structured RNA, sharing functions in developmental processes [125]. 
 
3.5 Maternal effect protein oskar (Drosophila melanogaster)  
The Drosophila maternal effect gene oskar encodes the posterior determinant 
responsible for the establishment of anterior-posterior polarity in Drosophila melanogaster 
and the formation of the abdomen and germ line of the future fly. The establishment of 
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anteroposterior patterning of the Drosophila embryo is determined by the polarization and 
translation prior to posterior localization of the oskar gene product (for review see [126-128]). 
The site of oskar RNA and protein localization within the oocyte determines where in the 
embryo primordial germ cells form and where the abdomen develops. Upon localization of 
oskar RNA and protein at the posterior pole, Oskar protein is required to maintain localization 
of oskar RNA throughout oogenesis. It was propose that initially localization of oskar RNA 
permits translation into Oskar protein and that subsequently Oskar protein regulates its own 
RNA localization through a positive feedback mechanism [66]. 
Mutations in the two oskar isoforms, which are necessary for the recruitment of various 
factors involved in posterior pole differentiation, result in a classical oskar mutant phenotype 
in which the flies lack germ cells and abdomens [129]. Common to these classical oskar 
alleles is that they all produce significant amounts of oskar mRNA. Surprisingly, two new 
oskar mutants that affect oskar mRNA abundance showed an even stronger phenotype, with 
arrest early in oogenesis, which suggests a functional role for oskar mRNA at an earlier stage 
in development [64]. The authors suggested that oskar mRNA, and not the Oskar protein, is 
responsible for the early oogenesis function. In a series of elegant experiments, the authors 
demonstrated that the early arrest of oogenesis could be complemented by oskar nonsense 
mutant alleles or the 3'-UTR of oskar mRNA [64]. Moreover, they showed that expression of 
the oskar 3′ untranslated region (3′UTR) is sufficient to rescue the egg-less defect of the RNA 
null mutant. 
It appears then that oskar acts as an mRNA during the embryonic stage and a non-
coding RNA during early oogenesis, independent of oskar coding capacity [64]. Oskar protein 
serves as a scaffold for the assembly of cytoplasmic structures essential for germ line 
development [66], the polar granules, at the posterior pole of the oocyte and embryo. 
Similarly, at earlier stages, oskar RNA may play a structural role by providing a similar 
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scaffold function for assembly of cytoplasmic complexes essential for development of the 
oocyte [64; 126].  
 
3.6 Transcription factor vegt (Xenopus laevis)  
An important feature of the Xenopus oocyte is that it is polarized along the 
animal/vegetal axis with the animal hemisphere containing the oocyte nucleus, and the vegetal 
hemisphere containing localized coding and non-coding RNA of maternal origin, involved in 
the control of endoderm, mesoderm, and germ cell specification during oogenesis. The coding 
VegT maternal mRNA encodes a transcription factor of the T-box family, related to 
Brachyury. VegT activates several endoderm-specific transcription factors, essential for the 
formation of the endodermal germ layer in blastula stages of development, and a group of 
TGFβ-related signaling molecules involved in mesoderm induction and required for proper 
gastrulation movements [70; 72; 73]. Indeed, overexpression of VegT in ectodermal explants 
generates endoderm in a dose-dependent manner [71]. Likewise, the antisense depletion of 
VegT transcripts caused abnormal distribution and/or expression of a subset of localized 
vegetal mRNA and prevents endoderm development [74]. Since then, VegT RNA has been 
shown to also fulfill a separate structural role in the cytokeratin network of primordial germ 
cells. The use of VegT morpholino that inhibits translation of VegT protein without affecting 
the level of targeted VegT mRNA, did not disperse the vegetally localized mRNA, indicating 
that a subset of localized mRNA is dependent on VegT mRNA but not on VegT protein [67]. 
VegT and other maternal ncRNA are anchored at the oocyte vegetal cortex, through 
integration into a cytoskeleton network of cytokeratin and actin [68]. Destruction of these 
RNA results in disruption of the cytokeratin cytoskeleton and defects in the anchoring of 
other localized RNA [67]. The structural function of VegT mRNA is independent of the VegT 
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protein, and organization of the cytokeratin cytoskeleton can be rescued by the injection of 
exogenous VegT mRNA [69]. 
VegT, like oskar cited above, belongs to a class of “localized” mRNA involved in 
ensuring a high-level synthesis of protein at the site where they are needed and/or preventing 
the protein from being synthesized in a region of the cell where it is not needed or could have 
a harmful effect. However, besides making a protein, as it is assumed from an mRNA, VegT 
and oskar RNA have an independent function as structural RNA. As a consequence, a normal 
cell phenotype may require both the function of the protein and the autonomous function of its 
mRNA (reviewed in [69]). 
 
3.7 A new function for p53 mRNA revealed in stress conditions 
The fascinating tumor suppressor p53 senses a variety of cellular stresses such as DNA 
damage, oncogenic signals or nutrient deprivation, and promotes cellular arrest and 
programmed cell death. In normal conditions, p53 protein is persistently degraded by the 
proteasome (for review see [56; 59; 60; 97-99]). In contrast, upon stress, both half-life of the 
p53 protein and translation of its mRNA are enhanced. The E3 ubiquitin ligase Mdm2 is the 
major regulator of p53 tumor suppressor activity. The well-known interaction between Mdm2 
and p53 proteins promotes p53 ubiquitination and targets it for degradation by the 
proteasome. Recently, p53 mRNA this time was shown to interact with Mdm2 protein with 
the effect of both stimulating p53 synthesis, but, more importantly, preventing Mdm2 from 
promoting p53 protein ubiquitination and degradation [95; 96]. The authors proposed that p53 
mRNA may act as a switch controlling the function of Mdm2 towards p53 [95]. Worth 
mentioning, the ability of Mdm2 to control both p53 synthesis and degradation are carried by 
the same genomic sequences in both mdm2 and p53. Hence, mutations within the coding 
region of this type of mRNA have to be carefully designed since they may affect both the 
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activity of the encoded protein and the activity of the mRNA as a functional RNA, and lead to 
results difficult to interpret. 
 
3.8 Steroid Receptor RNA activator (SRA) and SRAP (Mammalian) 
With the aim of discovering new partners of progesterone receptor (PR), with a co-
regulatory function, Lanz et al. identified a RNA molecule that they named SRA for Steroid 
Receptor RNA Activator [82]. SRA was an unusual partner since despite the presence of a 
long ORF no initiating methionines were identifiable. Since then, several studies have 
confirmed the capacity of SRA RNA to co-activate not only PR, but also many other nuclear 
receptors such as estrogen (ERα and β), progesterone, androgen and glucocorticoid receptors, 
as well as peroxisome proliferator-activated receptor (PPAR), all-trans retinoic acid receptor 
and many others (For a review, see [77; 78; 86]). More recently, transcriptional activity of 
other transcription factors including MyoD and GATA-3 has also been shown to be enhanced 
by SRA RNA [75; 80]. Structural characterization of SRA RNA highlighted that the core 
region of the messenger, consisting of exons 2 to 5, was necessary and sufficient to increase 
the ligand-dependent transcriptional activation of target genes by steroid receptors [82; 83]. 
Specifically, two stem-loop substructures, STR1 and STR7, were involved in ER co-
activation.  
By analogy to other described ncRNA, SRA transcripts may nucleate the assembly of 
co-regulators at their target genes and/or favor the correct nuclear localization of the different 
partners of the complex in response to external stimuli. Alternatively, SRA RNA may serve as 
a scaffold to stabilize large co-activator complexes. In favor of this hypothesis, SRA RNA has 
been already described embedded in nucleoprotein complexes containing positive regulators, 
including the receptor co-activator SRC-1 [82], the RNA helicases p68/p72 [75; 88] as well as 
the pseudouridine synthase Pus1p and Pus3p [76; 89; 90]. It was also shown to interact with 
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negative regulators such as the SMRT/HDAC1 Associated Repressor Protein SHARP [83; 
87] and the SRA stem-loop interacting RNA binding protein SLIRP [79].  
SRA transcripts have been identified in normal human tissues, with a higher expression 
in liver, skeletal muscle, adrenal and pituitary glands, whereas intermediate expression levels 
were observed in the placenta, lung, kidney and pancreas [82]. In some pathological cases, 
increased SRA RNA levels were reported like in breast and ovarian tumors [81; 84; 85]. 
Interestingly, levels of SRA expression could be characteristic of tumor grade or particular 
subtypes of lesions among different tumors. Indeed, serous ovarian tumors showed higher 
levels of SRA than granulosa tumor cells [81].  
Searching for transcriptional initiation sites, we identified new SRA RNA isoforms 
containing an additional exon 1 upstream of the core elements, with the peculiarity that these 
isoforms exhibited a longer predicted ORF, provided that the first intron was correctly 
spliced, as well as two ATG in the new exon. These features were not only compatible with 
the ability to encode a protein, a protein named SRAP was actually identified [80; 91; 93]. 
Interestingly, among the new isoforms, we also identified isoforms that displayed retention of 
intron 1 or splicing of exon 3 disrupting the ORF [80; 92; 94]. It appears then, that the SRA1 
gene products consist in fact of two distinct entities: functional RNA with the ability to 
enhance the activity of transcription factors through structural motifs in their core sequence, 
and a protein whose function remains to be deciphered. Although SRAP has direct effects on 
the activity of NR [91], we recently showed that SRAP did not interact with MyoD [80; 92; 
94]. However, we demonstrated that SRAP was able to interact with its RNA counterpart, 
leading to an overall inhibition of MyoD transcriptional activity and myogenic differentiation 
[80; 92; 94] (Figure 2).   
[Figure 2 may be inserted here] 
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Coding and non-coding SRA RNA isoforms co-exist in most of the cells. In 
pathological conditions, like in breast cancer, we described unbalanced expression levels in 
favor of non-coding SRA RNA in the three most invasive cell lines (MDA-MB-231, MDA-
MB-468, and BT-20) compared to MCF-10A1 breast cells isolated from benign tumors [94]. 
Likewise, breast tumors with a high progesterone receptor content, i.e. a poor prognostic 
factor, the balance was on the side of non-coding SRA RNA [130], suggesting that a 
perturbation in the balance between SRA could be associated with tumorigenesis [94]. During 
myogenic differentiation of human satellite cells from healthy but not from myotonic 
dystrophy donors, the ratio between non-coding and coding SRA isoforms was also elevated 
[80; 92; 94]. 
These accumulating data suggest that the overall effect of SRA on both molecular 
activities and cellular processes may result from the correct balance between coding and non-
coding SRA molecules. This statement may of course hold true for any other bifunctional 
RNA, and stresses the need to carefully evaluate the nature, i.e. coding vs. non-coding, of 
molecules present at a given time or in a given cell population. 
Therefore, any attempt to decipher functions of SRA or any RNA with dual functions, 
must take into account this remarkable bifunctional characteristic consisting of an RNA 
molecule that potentially encodes several proteins and ncRNA, with opposing functions. 
 
4. New functions for mRNA under pathological conditions 
Certain pathologies arise, not from the production of mutant proteins, but from a 
deleterious gain-of-function by ncRNA [131; 132]. In these RNA-dominant diseases, the toxic 
RNA has been implicated in the formation of nuclear foci and associated with degenerative 
disorders, mainly in brain, heart or skeletal muscle [133]. In addition, the normal function of 
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mRNA, i.e. to serve as an intermediate molecule for protein synthesis, is hijacked in that the 
modified RNA functions as a functional ncRNA, and thus interferes with physiological 
pathways. These modifications may include nucleotide triplets repeat expansions in the 3’ or 
5’ untranslated region of the mRNA, like in fragile X mental retardation 1 (FRM1) associated 
with adult neurodegenerative disorder and dystrophia myotonica-protein kinase (DMPK) 
transcripts associated with neuromuscular dystrophy (for reviews, see [100; 101]). It appears 
that the main pathogenic effect of the toxic RNA is to sequester binding proteins and 
compromise the regulation of alternative splicing. In myotonic dystrophy (DM), for example, 
the mutation does not directly cause the absence of an essential protein or a dysfunctional 
protein. The main effect is to induce misdistribution of splicing factors in cells, and the 
consequence is reversion to a pattern of alternative splicing that is characteristic of immature 
tissue [134; 135]. For example, the depletion by the CGG repeats of RNA-binding proteins 
such as Sam68, hnRNP-G and MBNL1, which are RNA-binding proteins involved in 
alternative splicing regulation. Loss of these factors leads to splicing-regulatory dysfunction 
[134-137]. Transcripts from the mutant DMPK allele accumulate in the nucleus and 
compromise the regulation of alternative splicing by sequestration of specific RNA-binding 
proteins such as CUGBP (Elav-like family), Elav-type ribonucleoprotein member 1 and 3 
(CUGBP and ETR-3), and MBNL1 in nuclear foci [100; 101; 138].  
Therefore, the repeat expansion characteristic of certain pathologies may fortuitously 
convert mRNA, with classical function as intermediate in protein synthesis, into functional 
RNA implicated in protein sequestration, through the acquisition of double-stranded hairpin 
structures conserved in all types of triplets [139; 140].  
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5. One gene, one pseudogene, two functions 
Pseudogenes are defective genes that have lost their ability to encode proteins. A 
pseudogene and its related gene often share a common ancestor, but have diverged as separate 
genetic entities over millions of years. According to recent studies, between 5 to 20% of 
human pseudogenes, which account for about 17,032 gene units (database build58, NCBI37), 
retain the ability to be translated (for reviews, see [141; 142]). However, pseudogenes are 
considered as false genes because of the absence of protein products resulting from deletions, 
insertions or mutations causing a frame shift or appearance of premature stop codons. There 
are three main types of pseudogenes, which differ in their origin; processed pseudogenes 
originate from retro-transposition of mRNA transcripts into the chromosome; duplicated 
pseudogenes are coming from gene duplication and successive mutations that render it 
deficient to be transcribed; unitary pseudogenes are genes which are disabled or deactivated 
without previous gene duplication (for reviews, see [141; 143; 144]). 
Whether pseudogenes are nothing more than inactivated copies of protein-coding genes 
or if they still retain a function is unclear, but some studies formally addressed the question. 
The most "obvious" mechanisms include the depletion of regulatory factors, or the production 
of antisense transcripts. For example, MKRN1, which encodes the makorin-1 Ring Finger 
Protein 1, a transcriptional co-regulator of androgen receptor and retinoic acid receptor and an 
E3 ligase for hTERT [104], and its retro-transposed pseudogene makorin1-p1, both contain 
receptor sites for transcriptional repressors [102]. Makorin1-p1 competes for the freely 
available repressor molecules that would otherwise submerge the gene’s receptors and 
severely inhibit its expression. This ‘depletion’ of the repressor by the pseudogene therefore 
favors protein synthesis from the gene [103]. Nitric oxide synthase (NOS) pseudogene 
includes a region of significant antisense homology to the neuronal NOS (nNOS)-encoding 
mRNA and acts as a natural antisense regulator of nNOS protein synthesis [145]. A more 
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novel mechanism involves depletion of miRNA otherwise implicated in regulation of 
expression of the gene counterpart. PTEN is a crucial, haplo-insufficient, tumor suppressor 
gene, whose expression is modulated by several miRNA. Transcripts originated from PTEN 
and from its pseudogene counterpart, PTENP1, show identical sequences in their 3’UTR 
regions. Since these regions are targets for miRNA, then transcripts from PTENP1 compete 
for miRNA interaction and lead to de-repression of PTEN and enhanced tumor-suppressor 
activity [105]. The same type of regulation was demonstrated for the oncogene KRAS by 
transcripts originated from its pseudogene KRAS1P [105].  
It is not question here, strictly speaking, of bifunctional RNA since both functions, 
coding and non-coding, are carried by two distinct genomic entities, although issued from a 
common ancestral gene. However, we are left here with a coding gene and its non-coding 
counterpart for which non-coding RNA can arise. As exposed above, these RNA can titrate 
regulatory factors and miRNA, and because of the probable multiplicity of their target genes, 
these RNA may affect regulation not only of their coding-gene counterpart but also of any co-
expressed gene modulated by the same entities. We believe that it will be important in the 
future to take into account these pseudo-transcripts as their interference with regulation of 
gene expression may go far beyond the cited examples. 
 
6. ncRNA vs. mRNA: Do we have to make the distinction ? 
In eukaryotes, mRNA undergo several processing steps before being translated. This 
includes addition of a cap structure at the 5′ end, splicing of introns from the body of the pre-
mRNA, and generation of a 3′ end, usually modified by the addition of a poly(A) tail. 
Although each of these reactions are biochemically distinct processes, they are interlinked and 
therefore, influence specificity and efficiency of one another [146]. While polyadenylation 
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has been implicated mainly in stabilization of the mRNA [147-149], capping is thought to be 
critical for the recognition and proper attachment of the ribosome, and therefore for 
translation (for a review [150; 151]). Thus, it is relatively surprising to note that numerous 
ncRNA are transcribed by polymerase II, processed like conventional mRNA and capped 
(Figure 3), although it has not been established yet that they are actually capable of producing 
a protein.  
[FIGURE 3 may be inserted here]  
Conversely, the main criterion which allows for the discrimination between an mRNA 
or a ncRNA is essentially based on its ability to encode a protein, and thus the length of its 
ORF, currently established at 100 amino acids (aa) [167]. However, depending of the length 
of the transcripts, longer ORF could occur by chance. Likewise, 5-10% of described proteins 
in Swiss-Prot are indeed shorter than 100 aa, even though the majority are variants of proteins 
longer than 100 aa [168]. Dinger et al. described an interesting model to take into account the 
length of the ORF and the length of the transcripts [122]. Thus, they established a cut-off 
above which the size of the ORF is not likely to appear randomly. We used their calculation 
to identify and measure the ORF length in databases containing 940 unique ncRNA sequences 
which have been identified and manually curated based upon extensive literature reviews 
[169]. As shown in Figure 4, 326 of the 940 sequences appeared to have a non-random ORF, 
with a 95% confidence. Even more surprisingly, when using an additional cut-off of 500 aa, 
which is very unlikely to occur by chance, 49 sequences still presented a coding capacity. 
[FIGURE 4 may be inserted here] 
The reverse is also true; short ORF <100 aa have been described [168; 170-174], and 
can be as short as 7 aa such as mccC7, a microcin heptapeptide involved in inhibition of 
protein synthesis in Entorobacteriaceae [175]. Another example is the already cited 
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bifunctional RNA enod40, that was first described as a ncRNA because of its very short ORF. 
Enod40 nonetheless encodes two small proteins of 12 and 24 aa [124].  
In essence, whether an mRNA can function as a ncRNA or if a ncRNA has the 
potential to encode a protein will not be assessed solely based on bioinformatics approaches, 
but will also require functional evaluation. Because many long ncRNA are likely to carry 
coding capacities like mRNA, and conversely, mRNA may operate as structural RNA, 
attempts to classify ncRNA or mRNA in strictly separate classes may become rapidly 
unrealistic.  
 
7. Conclusion 
More than a century after the discovery of RNA, and for nearly a decade, bifunctional 
RNA, i.e. RNA carrying both RNA-translatable and RNA-intrinsic functions, emerged as new 
players in molecular and cellular biology systems.  
We have just discussed here the few examples that are well documented and have 
provided a complementary view of the functional role of RNA in addition to their ability to 
encode proteins. Even though their number is limited, not fully understood and still 
necessitates to be closely studied, we are confident that new examples will add to the list 
quickly. Indeed, in yeast, it was predicted that about 5% of the genes may preserve both non-
coding and coding capacity [176; 177], and similar prediction was made in other species [178; 
179]. 
Hence, it becomes increasingly clear that we probably only looked through a keyhole 
in the last decades. By definition, the majority of ncRNA does not indeed have the ability to 
be translated into a long protein. However, it will probably prove interesting to test those that 
fulfill the criterions exposed above. In addition, new uncovered small peptides may also be 
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translated from ncRNA. It seems also that mRNA can form sub-structures and may be more 
implicated than previously thought in cellular processes, making studies of bifunctionality of 
RNA the next step in deciphering life complexity. We believe that awareness of 
bifunctionality of RNA is not only of great conceptual importance, but will be increasingly 
useful when it comes to decipher RNA function in a manner that discriminates this duality. 
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Figure legends 
 
Figure 1. A historic view of non-coding RNA.  
Indicated are some key dates in the discovery of non-coding RNA, from the first ribosomal 
RNA (rRNA) to the first description of the bifunctionality of SRA RNA, the funding member 
of this new category of RNA. SRA was first described as a non-coding RNA in 1999, as part 
of the steroid receptor coactivator-1 (SRC-1) complex. In 2003, the existence of an SRA-
associated protein called SRAP was then reported. 
 
Figure 2. A model for transcriptional co-regulation of MyoD following changes in the SRA 
RNA/SRA Protein balance during myogenic differentiation. 
(A) SRA1 gene products. SRA1 gene transcription leads to two major classes of isoforms, i.e. 
coding isoforms (blue/red ribbon) that preserve the ability to encode a protein SRAP (red 
puzzle), and non-coding isoforms that do not have an ATG start codon (blue ribbon) or that 
retain intron 1 (blue/green ribbon) disrupting the ORF. (B) Relationship between SRA 
expression, SRA function and myogenic differentiation. The balance between SRA-coding 
and SRA non-coding isoforms varies during myogenic differentiation in favor of SRA 
ncRNA. SRAP prevents the SRA RNA-dependent co-activation of MyoD (yellow puzzle) 
through the interaction of SRAP with its RNA counterpart. RRM, RNA Recognition Motif; 
STR7, RNA sub-structure; TSS, Transcriptional start sites. 
 
Figure 3. Schematic representation of mRNA primary and secondary structures, regrouping 
the classical features of a mRNA. The table on the bottom contains examples of ncRNA that 
preserve the classical features of a mRNA. 
Light blue, the 7 methyl-guanosine (m7G) cap; green, the 5’ and 3’ untranslated regions 
(UTR); dark blue, Open Reading Frame (ORF) region; red, the polyadenylated (polyA) tail. 
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Stem loops represent mRNA secondary structures. Pol II, polymerase II-dependent 
transcription; Splicing, RNA processed by splicing; Editing, RNA modifications other than 
capping and polyadenylation.  
 
Figure 4. Incidence of open reading frames (ORF) according to transcripts length in a ncRNA 
Dataset. 
A database (from RNAdb, http://research.imb.uq.edu.au/rnadb/) containing 940 unique 
ncRNA sequences which have been identified and manually curated based upon extensive 
literature reviews was used in this study [169]. (A) The longest ORF (ORF max, beginning 
with a methionine and finishing with a stop codon) predicted for each ncRNA sequence from 
the dataset was plotted against the length of the transcript. Each dot corresponds to a unique 
sequence from the database. The green curve represent incidences of randomly occurring 
ORF at 2 standard deviations from the mean [122], using the function y = 91.Ln(x) - 330, 
which has been proposed by Dinger et al. to discriminate non-coding from protein-coding 
transcripts in a transcript-length-dependent manner [122]. Even with these criterion, 326 of 
the 940 sequences data hold a potential ORF that does not occur by chance, with 95% 
confidence according to Dinger et al. [122]. The red line corresponds to the classical view of 
discrimination (from Fantom3, [167]) between coding and non-coding RNA, i.e. the ORF 
length with a cutoff of 300 nt (100 aa). (B) Cumulative frequency of sequences plotted against 
the ORF size. aa, amino acid; nt, nucleotide. 
 
